AzacitidineAntimetabolites, AntineoplasticMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicSurvival RateCell SurvivalTreatment OutcomeSurvivalChromatography, Supercritical FluidCompassionate Use TrialsLeukemia, Myeloid, AcuteInjections, SubcutaneousSurvival AnalysisDisease-Free SurvivalAnemia, RefractoryConsolidation ChemotherapyInduction ChemotherapyAnemia, Refractory, with Excess of BlastsDrug ApprovalDrug Administration ScheduleDNA MethylationAntineoplastic Combined Chemotherapy ProtocolsGraft SurvivalRetrospective StudiesDNA Modification MethylasesThalidomideInternational AgenciesRemission InductionEpigenomicsUnited States Food and Drug AdministrationTime FactorsCytarabineRecurrenceAntimetabolitesPrognosisBiological AvailabilityBlood TransfusionLeukemia, MyeloidApoptosisCell Line, TumorKaplan-Meier EstimateTetrazolium SaltsRandomized Controlled Trials as TopicFollow-Up StudiesDisease ProgressionTransplantation, HomologousMaximum Tolerated DoseAcute DiseaseNeoplasm StagingInfusions, IntravenousHematopoietic Stem Cell TransplantationCombined Modality TherapyEnzyme InhibitorsProportional Hazards ModelsAntineoplastic AgentsFatigueProspective StudiesLung NeoplasmsBreast NeoplasmsDose-Response Relationship, DrugDouble-Blind MethodNeoplasm Recurrence, LocalDisease Models, Animal